The US Food and Drug Administration’s guidance on clinical trials for smoking cessation or related indications changed little from draft to final published after four years, two commissioners and a stalled novel OTC product proposal.
The guidance, released on 28 April, reiterates the Center for Drug Evaluation and Research expectations for multiple clinical trials to demonstrate an investigational NRT product with characteristics different from...